Smallpox

Second U.S. contract awarded for smallpox vaccine

Published in Vaccine Weekly, October 27th, 2004

The U.S. government has awarded international biopharmaceutical company Bavarian Nordic a 3-year contract valued at a total of more than $141 million to further develop and manufacture 500,000 doses of its patented Imvamune smallpox vaccine, the latest phase in the government's smallpox vaccine development program.

"The U.S. government's decision to further develop and acquire Imvamune recognizes the advanced stage of our clinical research program and the need for a safe vaccine for the American public," said Peter Wulff, CEO, Bavarian Nordic.

"Ultimately, it is essential that the United States stockpiles a single, safe and effective smallpox vaccine...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-10-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry